ReviewNature reviews. Cardiology2012
Key advances in antihypertensive treatment.
Review in Nature reviews. Cardiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 53 citations in OpenAlex.
- Combined RAS Modulation: The Effect on Plasma and Tissue Angiotensin Peptide Levels.Physiological research · 2025Article
- Evolution of Angiotensin Peptides and Peptidomimetics as Angiotensin II Receptor Type 2 (AT2) Receptor Agonists.Biomolecules · 2020Article
- Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?Current cardiology reviews · 2020Review
- Article
- Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2017Observational
- Effect of antihypertensive agents - captopril and nifedipine - on the functional properties of rat heart mitochondria.Iranian journal of basic medical sciences · 2016Article
- New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?Current hypertension reports · 2015Review
- Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists.Drugs · 2015Review
- Systolic hypertension: an increasing clinical challenge in Asia.Hypertension research : official journal of the Japanese Society of Hypertension · 2015Review
- Physician underutilization of effective medications for resistant hypertension at office visits in the United States: NAMCS 2006-2010.Journal of general internal medicine · 2014Article
- ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis.PloS one · 2014Article
- Novel strategies for treatment of resistant hypertension.Kidney international supplements · 2013Article
- ERβ selective agonist inhibits angiotensin-induced cardiovascular pathology in female mice.Endocrinology · 2013Article
- Prevention of coronary artery disease: recent advances in the management of hypertension.Current atherosclerosis reports · 2013Review
- Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers.International journal of hypertension · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although various effective treatments for hypertension are available, novel therapies to reduce elevated blood pressure, improve blood-pressure control, treat resistant hypertension, and reduce the associated cardiovascular risk factors are still required. A novel angiotensin-receptor blocker (ARB) was approved in 2011, and additional compounds are in development or being tested in clinical trials. Several of these agents have innovative mechanisms of action (an aldosterone synthase inhibitor, a natriuretic peptide agonist, a soluble epoxide hydrolase inhibitor, and an angiotensin II type 2 receptor agonist) or dual activity (a combined ARB and neutral endopeptidase inhibitor, an ARB and endothelin receptor A blocker, and an endothelin-converting enzyme and neutral endopeptidase inhibitor). In addition, several novel fixed-dose combinations of existing antihypertensive agents were approved in 2010-2011, including aliskiren double and triple combinations, and an olmesartan triple combination. Upcoming fixed-dose combinations are expected to introduce calcium-channel blockers other than amlodipine and diuretics other than hydrochlorothiazide. Finally, device-based approaches to the treatment of resistant hypertension, such as renal denervation and baroreceptor activation therapy, have shown promising results in clinical trials. However, technical improvements in the implantation procedure and devices used for baroreceptor activation therapy are required to address procedural safety concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.